(Reuters) - The Food and Drug Administration approved label changes incorporating lower dosages for sleep medications containing zolpidem, a drug that can continue to affect patients' mental alertness even a day after its use. The regulator approved changes to the labels of Sanofi SA's Ambien, Ambien CR and Meda AB's Edluar on Tuesday. The agency said patients who take zolpidem extended-release drugs, such as Ambien CR, should not drive or take part in activities that require complete mental alertness the next day. ...
Get the complete story
No comments:
Post a Comment